Table 3.
Description of morbidity groups
| Morbidity groups a | ICD-10 codes | ATC codes | Codes added + or removed- b |
|---|---|---|---|
|
Unmodified diagnostic categories |
|
|
|
| Tuberculosis (03) |
A15A19,B90,K230,K673,K930,M011,M490,M900,N330,N740, N741,O980,P370 |
J04A |
J01GA01- J01GB04- |
| Human immunodeficiency virus disease (05) |
B20-B24,F024,R75,Z21 |
J05AE,J05AF,J05AG,J05AR, J05AX07-J05AX09 except J05AF08 |
J05AF05+ |
| Diabetes mellitus (22) |
E10-E14,G590,G632,H360, M141,N083,O24 |
A10 |
|
| Mental and behavioral disorders due to alcohol (25) |
F10 |
N07BB |
N07BB+ |
| Schizophrenia, schizotypal and delusional disorders (27) |
F20-F29 |
N05A , except N05AN |
N05AD0+ N05AL0+ |
| Mood [affective] disordersc (28) |
F30-F39 |
N06A,N06C,N05AN except N06AX01 and N06AX02 |
|
| Other mental and behavioral disordersd(29) |
F04-F09,F40-F99 not F803 |
N05B,N05C,N06B |
N05BD0+ N05BX0+ N05C + N06B+ |
| Alzheimer’s diseasee (30) |
F00,G30 |
N06D not N06DX02 |
|
| Multiple sclerosis* (31) |
G35 |
L03AB02,L03AB07,L03AB08, L03AX13 |
|
| Epilepsy (32) |
G40-G41,F803 |
N03 |
N03AA0+ |
| Hypertensive disease (38) |
I10-I15,O10-O11,O13-016 |
C02,C03 except C03C,C04AB, C07,C08,C09 |
C04AB + C07 + C08 + C09+ |
| Conduction disorders and cardiac arrhythmias (43) |
I44-I49 |
C01A,C01B,C01CA02,C01EB10 |
C01CA02+ |
| Heart failuref (44) |
I50 |
C01CA04, C01CA07,C01CE,C01CX,C03C |
C01CA04+ C01CX+ |
| Crohn’s disease and ulcerative colitis (65) |
K50-K51 |
A07EA,A07EC |
A07EA+ |
| Infections of the skin and subcutaneous tissue* (77) |
L01,L02,L08 |
D06,P03 |
|
| Hyperplasia of prostate (94) |
N40 |
G04BD,G04C |
G04BD + G04C+ |
| Inflammatory diseases of female pelvic organs* (97) |
N70-N77, except N740 and N741 |
G01 |
|
| Poisoning by drugs and biological substances* (122) |
T36-T65 |
V03AB,H04AA01 |
|
|
Subgroups of diagnostic categories |
|
|
|
| Paludism* (06-) |
B50-B54 |
P01B not P01BA02 |
|
| Parasitosis* (06-) |
B55-B83, B89 |
P01A,P01C,P02 |
|
| Hepatitis B or C (06-) |
B16-B18 |
L03AB01,L03AB04,L03AB05,L03AB06,L03AB09,L03AB10, L03AB11, J05AF08, J05AF10, J05AF11 |
J05AB04- J05AF05- L03AB01+ L03AB06+ L03AB09+ L03AB11+ |
| Viral diseases* (06-) |
A60,A80-A99,B00-B15,B19, B25-B34,B941,B942,B97,J12, J171,J203-J207,J210 |
J05AA, J05AB, J05AC03, J05AD, J05AX except J05AX07-J05AX09 |
|
| Anemia – nutritional* (20-) |
D50-D53 |
B03A, B03B |
|
| Non nutritional anemia g (20-) |
D55-64 |
B03XA |
|
| Neutropenia* (21-) |
D70 |
L03AA |
|
| Thyroid disorders (23-) |
E00-E07 |
H03 |
|
| Other endocrine, nutritional and metabolic diseases* (23-) |
remainder of E00-E90 |
H01AB, H01AC, H01AX, H01C except H01CB01 |
|
| Obesity* (23-) |
E66 |
A08 |
|
| Hyperlipidemia (23-) |
E780-E785 |
C10 |
|
| Mental and behavioral disorders due to opioids* (26-) |
F11,F19 |
N07BC |
|
| Mental and behavioral disorders due to tobacco (26-) |
F17 |
N07BA |
N07BA+ |
| Migraine (34-) |
G43 |
N02C |
N02C+ |
| Parkinson’s disease (34-) |
G20-G22 |
N04,except N04BC08 |
N04BC01+ N04BC06 + h N04BC07+ |
| Conjunctivitis* (36-) |
H10 |
S01A, S01GX |
|
| Glaucoma (36-) |
H40, H42 |
S01E |
|
| Eye inflammation* (36-) |
H00-H05,H11-H16,H20, H22 |
S01B, S01C |
|
| Disorders of external ear* (37-) |
H601-H609,H62 |
S02, S03 |
|
| Vertigo* (37-) |
H81,H82 |
N07C |
|
| Influenza* (49-) |
J09-J11 |
J05AH, J05AC02 |
|
| Other acute upper respiratory infections* (49-) |
J00-J06, not J020,J028,J030, J038 |
R01, R02, R05 |
|
| Other diseases of upper respiratory tract – allergy (53-) |
J30,L50 |
R06, V01 |
R06 + V01+ |
| Hemorrhoids* (69-) |
I84, O224, O872 |
C05A |
|
| Functional disorders of the digestive system* (76-) |
K58, K59 |
A03, A06, A07DA, A07B, A07CA |
|
| Psoriasis (78-) |
L40 |
D05, L04AA21, L04AA15 |
D05 + L04AA21+ L04AA15+ |
| Dermatitis* (78-) |
L20-L39, not L303 |
D07, D11AX14, D11AX15 |
|
| Acne* (79-) |
L70,L718,L719,L730 |
D10 |
|
| Gout (83-) |
M10 |
M04A |
|
| Osteoporosis (89-) |
M80-M82 |
H05, M05BA, M05BB |
H05 + M05BA + M05BB+ |
| Transplanted organ status (129-) |
K771,K932,L991,N165,T860, T861-T864,T8681,T8682,Z94 |
L04AA02-10, L04AX01, L04AC01, L04AC02, L04AD01, L04AD02 |
|
|
Multiple morbidities groups |
|
|
|
| Gastroenteritis of presumed infectious origin* (01–02) |
A00-A09, not A064-A066, K521 |
A07A, A07F |
|
| Ischemic heart diseases (39–41) |
I20-I25 |
C01DA, C01DX12, C01DX16 |
C01DX12+ |
| Reactive airway diseasei (54, 55) |
J40-J47 |
R03 |
R03AA + R03AB + R03BZ + R03CA + R03CB+ |
| Diseases of esophagus and peptic ulcer (59–61) |
K20-K31, not K230 and K231 |
A02BA- A02BD, A02X02 |
|
| Malignant neoplasm (07–15) |
C00-C97 |
A04AA, A04AD12, L01, L02, L03AC01, L03AX03, L03AX12 L04AX02, V03AF, V03AG, V03AH, V10A, V10B, V10XX01 |
L03AA-m A04AD12+ L02+ L03AC01+,L03AX03+,L03AX12+ L04AX02 + V03AF + V03AG + V03AH + V10A + V10B + V10XX01+ |
| Inflammatory polyarthritis and connective tissue disorders (83,85-)j |
M05-M09, M30-M36, M45 |
H02A, H02B,L04AA13,L04AB01, L04AB04, L04AX03, M01B, M01CA, M01CB, P01BA02 |
L04AX03+ M01B + M01CA+ |
| Pain (80-83-,85-88-,111,112-)k |
M50-M51,M54,R07,R10, R30, R51, R52, remainder of M60-M79 |
M01A, M03B, M03C, M09, N02A, N02B |
M03B + M03C + M09+ N02B+ |
| Mycosis (06-,50-)* |
B35-B49, J172 |
D01, J02 |
|
| Bacterial infection or septicemia* (04,06-,50-,51-,88-) |
A064-A066, A20-A79 (except A30, A31, A60), B95,B96, B99, D733, E321, G00, G01, G042, G060-G062, G07, H600, J020, J028, J030, J038, remainder of J13-J20, J36, J390, J391, J851-J853, K046, K047, K1020, K1021, K113, K122, K351, K570, K572, K574, K578, K61,K630, K750, L00, L03-L05, M00, M010-M013, M03, M600, M630-M632, M650, M651; M680, M710, M711, M730, M731, N151, N160, N340, N412, N450, N459, N751, N764, O85, O911 |
J01 |
|
| Thrombo-embolic risk or disease (34-, 42-,45-,46-,48,101-,102-,106-)l |
G08, I260,I269,I2720, I63-I66,I676, I693, I694, I698, I70, I731,I74, I77, I80-I82, O032, O037, O042, O047, O052, O057, O062, O067, O072, O077, O082, O223, O225, O871, O873 |
B01A |
|
| Hemorrhage risk or disease* (21-, 45-,46-) | D65-D68, D693-D699 | B02,L03AC02 |
aThe numbers identifying groups are those of the International Shortlist for Hospital Morbidity Tabulation (ISHMT) - Eurostat/OECD/WHO; with dash indicating subgroups. Categories not included in the most recent RxRisk model18 are indicated with an asterisk*.
bCodes removed or added to those of Kuo et al.14
cThe RxRisk-V distinguishes bipolar disorders (ATC code N05AN) and depression.
dThis category is defined as anxiety and tension in the RxRisk-V (hypnotics not retained as screen).
eThis category is defined as dementia in the RxRisk-V.
fThe RxRisk-V split hypertension in hypertension and congestive heart failure/hypertension, the latter detected by loop diuretics, Angiotensin converting enzyme inhibitors and Angiotensin II receptors blockers.
gDefined as end stage renal disease in the RxRisk-V.
hATC distinguishes, according the dose, the use of the two dopamine agonists bromocryptin and cabergolin N04BC01 , N04BC06: low dose for prolactin inhibition and high dose in parkinsonism.
iAsthma, chronic obstructive pulmonary disease and bronchiectasis.
jRheumatic conditions for original CDS and steroid responsive conditions for Rxrisk.
kThe RxRisk-V distinguishes pain(opioid) from pain and inflammation (NSAI).
lThe RxRisk-V distinguishes anti-platelet from anticoagulant.
mIn our category neutropenia.